HD-OPM Archive
Topics › Cancer

Everolimus plus hydroxychloroquine may prevent breast cancer recurrence

Louis Nervegna · Jan 26, 2026 · ♥ 6 reactions · 9 comments · original Facebook post
CancerAging & longevity
AI summary & key facts

Louis shares a Penn study finding everolimus plus hydroxychloroquine dramatically reduced dormant tumor cells that cause breast cancer recurrence. Not directly heart-related.

An mTOR inhibiting drug similar to rapamycin (everolimus) plus a quinoline anti-malarial drug (hydroxychloroquine) might prevent recurrence of breast cancer.

See this previous post in the rapamycin group for a discussion of the mechanisms involved:

facebook.com/share/p/17xWTZj9n1

Quoted:

A recent Penn study from Angela DeMichele, MD, and Lewis Chodosh, MD, PhD, found that everolimus and hydroxychloroquine—two medicines already approved for other conditions—can dramatically reduce the dormant tumor cells that often cause cancer recurrence.

Penn Medicine's David Fajgenbaum, MD, a trailblazer in the field of drug repurposing, highlights how this breakthrough serves as a powerful reminder that some of the most promising cures might already be sitting on pharmacy shelves.

#rapamycinHD #mtorHD #hcqHD #chloroquineHD #everolimusHD #cancerHD #breastcancerHD

← newer: Lactate from high-intensity exercise boosts BDNF; metformin older: Steel-cut oats have a glycemic index of 42; instant oats 83 →